{
    "clinical_study": {
        "@rank": "51835", 
        "acronym": "LUNAR", 
        "arm_group": [
            {
                "arm_group_label": "BOL-303259-X", 
                "arm_group_type": "Experimental", 
                "description": "BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s)."
            }, 
            {
                "arm_group_label": "Timolol", 
                "arm_group_type": "Active Comparator", 
                "description": "Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s)."
            }
        ], 
        "brief_summary": {
            "textblock": "In participants with a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT),\n      the primary objective is to demonstrate that the mean IOP reduction after 3 months of\n      treatment with BOL-303259-X once daily (QD) is non-inferior to timolol maleate 0.5% twice\n      daily (BID). The secondary objective is to demonstrate the superiority of BOL-303259-X QD to\n      timolol maleate 0.5% BID. This assessment will be performed if the non-inferiority of\n      BOL-303259-X QD to timolol maleate 0.5% BID is determined. An open label safety phase will\n      be conducted at the end of Visit 6 (3 months) where all participants will receive\n      BOL-303259-X QD for an additional 3 months."
        }, 
        "brief_title": "Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Open-Angle Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants must have a diagnosis of OAG (including pigmentary or pseudoexfoliative)\n             or OHT in 1 or both eyes.\n\n          -  Participants must meet the following IOP requirements at Visit 3\n\n          -  mean/median IOP \u2265 26 mmHg at a minimum of 1 time point, \u2265 24 mmHg at a minimum of 1\n             time point, and \u2265 22 mmHg at 1 time point in the same eye\n\n          -  IOP \u2264 36 mmHg at all 3 measurement time points in both eyes.\n\n          -  Participants with a best-corrected visual acuity (BCVA), using the Early Treatment of\n             Diabetic Retinopathy Study (ETDRS) protocol, of +0.7 logMAR units (Snellen equivalent\n             of approximately 20/100) or better in either eye.\n\n        Exclusion Criteria:\n\n          -  Participants with known hypersensitivity or contraindications to latanoprost, NO\n             treatment, timolol maleate, other beta-adrenergic receptor antagonists or any of the\n             ingredients in the study drugs.\n\n          -  Participants with a central corneal thickness greater than 600 \u03bcm in either eye.\n\n          -  Participants with advanced glaucoma and participants with a cup/disc ratio greater\n             than 0.8 or a history of split fixation, or a field loss threatening fixation in\n             either eye.\n\n          -  Participants who do not have an intact posterior capsule in either eye .\n\n          -  Participants with aphakia in either eye.\n\n          -  Participants with previous or active corneal disease in either eye.\n\n          -  Participants with current or a history of severe dry eye in either eye.\n\n          -  Participants with current or a history of optic disc hemorrhage in either eye.\n\n          -  Participants with current or a history of central/branch retinal vein or artery\n             occlusion in either eye.\n\n          -  Participants with current or a history of macular edema in either eye.\n\n          -  Participants with very narrow angles (3 quadrants with less than Grade 2 according to\n             Shaffer's anterior chamber angle grading system) and participants with angle\n             closure,congenital, and secondary glaucoma, and participants with history of angle\n             closure in either eye.\n\n          -  Participants with a diagnosis of a clinically significant or progressive retinal\n             disease in either eye.\n\n          -  Participants with any intraocular infection or inflammation in either eye within 3\n             months(90 days) prior to Visit 1 (Screening).\n\n          -  Participants with a history of ocular laser surgery in either eye within the 3\n             months(90 days) prior to Visit 1 (Screening).\n\n          -  Participants with a history of incisional ocular surgery or severe trauma in either\n             eye within 3 months (90 days) prior to Visit 1 (Screening)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "393", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749930", 
            "org_study_id": "770"
        }, 
        "intervention": [
            {
                "arm_group_label": "BOL-303259-X", 
                "description": "BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning", 
                "intervention_name": "BOL-303259-X", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Timolol", 
                "description": "Timolol will be administered BID once in the morning and once in the evening.", 
                "intervention_name": "Timolol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BOL-303259-X", 
                    "Timolol"
                ], 
                "description": "All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).", 
                "intervention_name": "BOL-303259-X", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Timolol", 
                "Maleic acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Intraocular pressure", 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14609"
                }, 
                "name": "Bausch & Lomb Inc."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension", 
        "other_outcome": {
            "description": "Following assessments through 3 months (Visit 6), all participants, irrespective of previous randomization, will convert to a single open label safety arm receiving BOL-303259-X QD in the evening for an additional 3 months Visit 6 through Visit 7. Adverse events will be recorded.", 
            "measure": "Incidence of Adverse events", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "overall_contact": {
            "email": "kimberly.rossman@bausch.com", 
            "last_name": "Kim Rossman, MBA", 
            "phone": "(973) 360-6412"
        }, 
        "overall_official": {
            "affiliation": "Bausch & Lomb Incorporated", 
            "last_name": "Jason Vittitow", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mean intraocular pressure (IOP) in study eye measured at the specified time points: 8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3).", 
            "measure": "Mean IOP Reduction", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749930"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of participants with IOP \u2264 18 mm Hg consistently at all 9 time points in the first 3 months", 
                "measure": "IOP \u2264 18 mm Hg", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Proportion of participants with IOP reduction \u2265 25% consistently at all 9 time points in the first 3 months", 
                "measure": "IOP reduction \u2265 25%", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Bausch & Lomb Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}